迪瑞医疗：保持国际成长根基，深耕智能化产品研发

Core Viewpoint - The financial performance of Di Rui Medical has significantly declined in the first three quarters of 2025, with a revenue drop of 60.12% and a net profit loss of 87.25 million yuan, reflecting challenges in the domestic market and the impact of industry competition and pricing policies [1][2]. Financial Performance - The company's revenue for the first three quarters was 469 million yuan, a decrease of 60.12% year-on-year [1]. - The net profit attributable to shareholders was -87.25 million yuan, representing a year-on-year decline of 145.31% [1]. Strategic Adjustments - Di Rui Medical is focusing on risk mitigation, stability, and industrial development, which includes optimizing the board structure and adjusting the management team to include individuals with operational backgrounds [1]. - The company has clarified its R&D direction and areas of focus, aiming to fulfill the digitalization and intelligence responsibilities of the China Resources medical industry [1]. Market Expansion - The company is pursuing a dual-driven strategy for domestic and international markets, emphasizing localized management and product upgrades [1]. - Di Rui Medical has achieved some success in international markets, with several high-speed models registered in various countries, including India, the Philippines, and Turkey, showing year-on-year growth [1]. Domestic Market Challenges - The domestic market is under pressure due to competition and centralized procurement policies affecting reagent prices, prompting the company to adjust pricing policies and optimize performance assessments [2]. - The company plans to conduct a "100-day offensive" campaign in the fourth quarter to enhance performance and overcome challenges [2]. Shareholder Developments - The controlling shareholder, Huade Xinrun, has released a pledge on 45.6 million shares, which accounts for 59% of its holdings and 16.72% of the company's total share capital, resulting in no pledged shares remaining [2].